Overview

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Men and post- or induced menopausal women with ER[+] and/or PgR[+], HER2[- ] advanced BC, with centrally-confirmed PI3KCAMut who progressed to an aromatase inhibitor (AI) regimen.
Phase:
Phase 2
Details
Lead Sponsor:
MedSIR
Collaborator:
Novartis
Treatments:
Fulvestrant
Metformin